Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy

PURPOSE: Pegfilgrastim is a pegylated form of filgrastim, a recombinant protein of granulocyte colony-stimulating factor, that is used to reduce the risk of febrile neutropenia (FN). Here, we report the results of a phase III trial of pegfilgrastim in breast cancer patients receiving docetaxel and c...

Descripción completa

Detalles Bibliográficos
Autores principales: Kosaka, Yoshimasa, Rai, Yoshiaki, Masuda, Norikazu, Takano, Toshimi, Saeki, Toshiaki, Nakamura, Seigo, Shimazaki, Ryutaro, Ito, Yoshinori, Tokuda, Yutaka, Tamura, Kazuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381099/
https://www.ncbi.nlm.nih.gov/pubmed/25576433
http://dx.doi.org/10.1007/s00520-014-2597-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381099/
https://www.ncbi.nlm.nih.gov/pubmed/25576433
http://dx.doi.org/10.1007/s00520-014-2597-1

Ejemplares similares